Szemészet, 2016 (153. évfolyam, 1-4. szám)

2016-12-01 / 4. szám

Current treatment of diabetic macular edema

receiving panretinal photocoagulation. Retina 2011; 31:

1009-1027.

35. Haller JA, Qin H, Apte RS, et al, Diabetic Retinopathy Clinical Research Network Writing Committee. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117: 1087-1093.

36. Haritoglou C, Kernt M, Wolf A. [Diabetic maculopathyl. Ophthalmologe 2015; 112: 871-883.

37. Heier JS, Bressler NM, Avery RL, et al; American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. JAMA Ophthalmol 2016; 134: 95-99.

38. Hikichi T, Fujio N, Akiba J, et al. Association between the short-term natural history of diabetic macular edema and the vitreomacular relationship in type II diabetes mellitus. Ophthalmology 1997; 104: 473-478.

39. Ho AC, Scott lU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology 2012; 119: 2179-2188.

40. Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015; 122: 367-374.

41. Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012; 130: 1145-1152.

42. Jampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. JAMA 2014; 311: 2269-2270.

43. Jonas JB, Söfker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001; 132: 425-427.

44. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003; 27: 281-291.

45. Kim SJ, Flach AJ, Jampol LM. Nonsteroidal anti-inflammatory drugs in ophthalmology. Surv Ophthalmol 2010; 55: 108-133.

46. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989; 107: 237-243.

47. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989; 107: 244-249.

48. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XV: The long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16.

49. Klein R, Sharrett AR, Klein BE, et al. ARIC Group. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the atherosclerosis risk in communities study. Ophthalmology 2002; 109: 1225-1234.

50. Kohner EM, Stratton IM, Aldington SJ, et al. UK Prospective Diabetes Study (IKPDS1 Group. Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52). Diabet Med 2001; 18: 178-184.

51. Korobelnik JE Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247-2254.

52. Kriska AM, LaPorte RE, Patrick SL, et al. The association of physical activity and diabetic complications in individuals with insulin-dependent diabetes mellitus: the Epidemiology of Diabetes Complications Study—VII. J Clin Epidemiol 1991; 44: 1207-1214.

53. Kumagai K, Hangai M, Ogino N, et al. Effect of internal limiting membrane peeling on long-term visual outcomes for diabetic macular edema. Retina 2015; 35: 1422-1428.

54. Liegl R, Langer J, Seidensticker F et al. Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. PLoS One 2014; 9:e113981.

55. Lopes-Virella ME Baker NL, Hunt KJ, et al; DCCT/EDIC Study Group. High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care 2012; 35: 1333-1340.

56. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sei 2004; 45: 910-918.

57. Milibák T: A diabéteszes maculopathia diagnosztikája és kezelése. Szemészet 2012; 4: 243-259.

58. Mitchell P Bandello F Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.

59. Muether PS, Droege KM, Fauser S. Vascular endothelial growth factor suppression times in patients with diabetic macular edema treated with ranibizumab. Br J Ophthalmol 2014; 98: 179-181.

60. Muni RH, Kohly RP Lee EQ, et al. Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial. JAMA Ophthalmol 2013; 131: 514-521.

61. Neubauer AS, Langer J, Liegl R, et al. Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparison with conventional macular laser. Clin Ophthalmol 2013; 7: 121-128.

62. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801.

63. Papp A, Pregun T, Szabó A, Schneider M, Seres A, Vargha R Hagyó К, Németh J. Intravitreális triamcinolon acetonid a diffúz diabeteses macula-ödéma kezelésében. Szemészet 2007; 144: 21-26.

64. Qi HR Bi S, Wei SQ, et al. Intravitreal versus subtenon triamcinolone acetonide injection for diabetic macular edema: a systematic review and meta-analysis. Curr Eye Res 2012; 37: 1136-1147.

65. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24- month data: report 3. Arch Ophthalmol 2012; 130: 972-979.

66. Ryan EH Jr, Han DR Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006; 26: 562-570.

67. Sears JE, Hoppe G. Triamcinolone acetonide destabilizes VEGF mRNA in Muller cells under continuous cobalt stimulation. Invest Ophthalmol Vis Sei 2005; 46: 4336-4341.

68. Seres A, Papp A, Süveges I. A maculopathia diabetica lézerkezeléséről. Szemészet 2000; 137: 163-171.

69. Shah AR, Xi M, Abbey AM, et al. Short-term efficacy of intravitreal dexamethasone implant in vitrectomized eyes with recalcitrant diabetic macular edema and prior anti-VEGF therapy. J Ophthalmic Vis Res 2016; 11: 183-187.

70. Shimura M, Yasuda K, Minezaki T, Noma H. Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol 2016; 60: 401-407.

71. Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol 2012; 6: 1259-1269.

72. Snow V, Weiss KB, Mottur-Pilson C. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence